

Prescription Drug Price Transparency: Public Interest List

Annelisa Steeber




health.state.mn.us




RxPT Work and Intersections with the PDAB

Health Economics Program (HEP) Rx Program Areas



Reporting Streams under Prescription Drug Price Transparency Act (MS 62J.84)



MDH Obligations under the Prescription Drug Affordability Act

- Rx drug price information; decision to conduct cost review (MS 62J.90)
 - Provide **RxPT data** to the Board [62J.90, subd. 1(a)]
 - Provide technical assistance to the Board related to **identifying drug products** (NDCs) that meet the criteria under 62J.90, subd. 2(a) [62J.87, subd. 5(b)]
 - Provide **consultation** to the Board in identifying prescription drug products with costs that create significant affordability challenges for the state health care system or for patients [62J.90, subd. 2(b)]
- Prescription Drug Affordability Advisory Council (MS 62J.88)
 - Delegate one staff to be a member of the Advisory Council [62J.88 subd. 2]

RxPT-PI List vs. List of Drug Products for PDAB

RxPT Public Interest List

- List based on methodology identified by MDH
- List activates reporting & submitted <u>data</u> <u>published online</u>
- Quarterly lists


- PDAB Selection of Drug Products: 62J.90, subd. 2(a)
- NDC-level list
- Produced by MDH-RxPT
- Aimed at ID-ing drugs we want to understand better
- List criteria defined in Statute
- PDAB may initiate cost reviews of listed drugs
- Lists are largely stable within a 12month period



RxPT Expansion – Public Interest

New Drugs of Substantial Public Interest Reporting

- Reporting entities
 - Drug manufacturers
 - Wholesalers
 - Pharmacy benefit managers (PBMs)
 - Pharmacies
- Data
 - Prices along supply chain, including inputs and outputs like costs, rebates, fees, patience assistance, and reimbursements
- Based on a quarterly list of drugs of substantial public interest identified by MDH




Source: <u>https://healthpolicy.usc.edu/research/flow-of-money-through-the-pharmaceutical-distribution-system/</u>


Process for One Reporting Cycle



Process Overview



Therapeutic Class & Drug Families



PI Data

PI Data at the NDC level:

Manufacturers

- Price History • Manufacturing, Distributing, & Marketing Costs
- Units Sold
- Revenue
- Profit
- Rebates Paid
- Patient Assistance
- Foreign Pricing

- Units
- Acquired • Acquisition
- Cost

Wholesalers


- Rebates Received
 - Units Sold
 - Revenue
- Rebates Paid

- Units PBMs
 - Administered
 - Reimbursement Received
 - Rebates Received
 - Admin Fee Received
 - Rebates Paid

• Units

Pharmacies

- Acquired
- Rebates Received
- Pricing Units Dispensed
- Payment Received
- Average Cash Price



How we're thinking about the PI list

"providing greater consumer awareness of the factors contributing to the cost of prescription drugs in the state" (MS 62J.84)



- Enhance understanding and provide transparency into the factors contributing to the cost of prescription drugs in the state.
- Look beyond manufacturers.
- Focus on drug pricing at the systemic level; most lists will focus on a single feature of the supply chain.
- May repeat a particular list of drugs; however, MDH will aim to explore different aspects of the market with each list.
- Lists will focus on the **drug family** level.



First List of Drugs of Substantial Public Interest

Methodology

Calculated: % difference between total list price and total claims paid amount

Filtered: Average Claims Paid Amount greater than \$100 & % Difference > 125%

Grouped: Resulting drugs by drug product family

Selected: The 10 drug product families (including all NDCs) with the greatest \$ difference

NDC-Level Calculations

- Average Total Claims Paid Amount = (sum of (claim paid amount * number of claims at that \$ amount)) /number of claims
- Average Total List Price = sum of (list price * number of claims during list price effective period) / number of claims
- % Difference = Total Claims Paid Amount / Total List Price

The List

Drug Family	Treatment or Purpose	Count of NDCs	Total Claims	Total of WAC		Total Paid Amount		Difference*
Abiraterone Acetate Tablet	Cancer	35	5,499	\$	4,884,579	\$	19,237,685	294%
Capecitabine Tablet	Cancer	39	3,925	\$	437,774	\$	3,087,526	605%
Dimethyl Fumarate Capsule Delayed Release	Multiple sclerosis (MS)	27	3,191	\$	7,293,900	\$	13,192,104	81%
Emtricitabine-Tenofovir Disoproxil Fumarate Tablet	HIV, PrEP	26	16,415	\$	1,313,035	\$	13,390,587	920%
Everolimus Tablet	Immuno-suppressant	38	1,011	\$	7,626,430	\$	9,569,824	25%
Glatiramer Acetate Solution Prefilled Syringe	Multiple sclerosis (MS)	8	7,056	\$	25,300,371	\$	28,836,961	14%
Imatinib Mesylate Tablet	Cancer	36	3,462	\$	2,949,368	\$	10,543,139	257%
Lacosamide Tablet	Anti-seizure	71	22,345	\$	11,486,951	\$	13,638,024	19%
Methylphenidate HCl Tablet Extended Release	ADHD	55	150,624	\$	44,156,967	\$	46,376,225	5%
Pancrelipase (Lipase- Protease-Amylase) Capsule Delayed Release Particles	Digestive aid	29	18,205	\$	31,338,420	\$	39,003,881	24%
Total		364	231,733	\$	136,787,795	\$	196,875,956	



Thank You! And what questions do you have for us?